Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 58Prostatic Neoplasms, Castration-Resistant 5Neoplasm Metastasis 4Metastatic Castration-resistant Prostate Cancer 4Prostatic Diseases 3Neoplasms 3Breast Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Male Urogenital Diseases 2Genital Diseases, Male 2Bulbo-Spinal Atrophy, X-Linked 2Biochemically Recurrent Prostate Cancer 2Urogenital Neoplasms 1Urogenital Diseases 1Thrombocytosis 1Refractory or Relapsed Solid Tumors 1Prostate Cancer Non-Metastatic 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms by Site 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

Rosuvastatin Calcium 2technetium 99m HYNIC-duramycin 1eltrombopag 1darolutamide 1Magnetic Iron Oxide Nanoparticles 1Gelatin 1Decision Support Techniques 1Contrast Media 1Cell Death 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Healthy Volunteers × darolutamide × Clear all
NCT02671097 2016-09-08

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Bayer

Phase 1 Completed
30 enrolled

Healthy Volunteers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡